载脂蛋白B脂蛋白颗粒数与心肌梗死风险的相关性
提示apoB颗粒数是心梗风险的主要驱动因素。
要点
- apoB颗粒数是心梗风险的独立预测因子,优于胆固醇或甘油三酯含量。
- 在他汀治疗的二级预防患者中,仅apoB与心梗风险独立相关。
- 降低所有含apoB脂蛋白颗粒浓度应是治疗策略的重点。
核心结论
- 心梗风险最佳由含apoB脂蛋白颗粒数反映,独立于脂质含量或脂蛋白类型。
- apoB可能是动脉粥样硬化的主要驱动因素,治疗应聚焦降低所有含apoB脂蛋白浓度。
研究设计与样本
- UK Biobank中位随访11.1年(IQR 10.4-11.8),临床试验中位随访2.5年(IQR 2.0-4.7)。
主要发现
- 一级预防队列中,apoB、非HDL-C和TG各自与心梗发生相关。
- 二级预防队列中,同样仅apoB与心梗相关。
- 调整apoB后,TG与LDL-C比值与心梗风险无关联。
临床怎么用
- 临床风险评估和治疗监测应优先关注apoB颗粒数,而非仅LDL-C或TG水平。
- 降脂治疗目标应聚焦降低所有含apoB脂蛋白颗粒浓度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Lipid management typically focuses on levels of low-density lipoprotein cholesterol (LDL-C) and, to a lesser extent, triglycerides (TG). However, animal models and genetic studies suggest that the atherogenic particle subpopulations (LDL and very-low-density lipoprotein [VLDL]) are both important and that the number of particles is more predictive of cardiac events than their lipid content. OBJECTIVE: To determine whether common measures of cholesterol concentration, TG concentration, or their ratio are associated with cardiovascular risk beyond the number of apolipoprotein B (apoB)-containing lipoproteins. DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort analysis included individuals from the population-based UK Biobank and from 2 large international clinical trials, FOURIER and IMPROVE-IT. The median (IQR) follow-up was 11.1 (10.4-11.8) years in UK Biobank and 2.5 (2.0-4.7) years in the clinical trials. Two populations were studied in this analysis: 389 529 individuals in the primary prevention group who were not taking lipid-lowering therapy and 40 430 patients with established atherosclerosis who were receiving statin treatment. EXPOSURES: ApoB, non-high-density lipoprotein cholesterol (HDL-C), LDL-C, and TG. MAIN OUTCOME AND MEASURES: The primary study outcome was incident myocardial infarction (MI). RESULTS: Of the 389 529 individuals in the primary prevention group, 224 097 (58%) were female, and the median (IQR) age was 56.0 (49.5-62.5) years. Of the 40 430 patients with established atherosclerosis, 9647 (24%) were female, and the median (IQR) age was 63 (56.2-69.0) years. In the primary prevention cohort, apoB, non-HDL-C, and TG each individually were associated with incident MI. However, when assessed together, only apoB was associated (adjusted hazard ratio [aHR] per 1 SD, 1.27; 95% CI, 1.15-1.40; P < .001). Similarly, only apoB was associated with MI in the secondary prevention cohort. Adjusting for apoB, there was no association between the ratio of TG to LDL-C (a surrogate for the ratio of TG-rich lipoproteins to LDL) and risk of MI, implying that for a given concentration of apoB-containing lipoproteins, the relative proportions of particle subpopulations may no longer be a predictor of risk. CONCLUSIONS AND RELEVANCE: In this cohort study, risk of MI was best captured by the number of apoB-containing lipoproteins, independent from lipid content (cholesterol or TG) or type of lipoprotein (LDL or TG-rich). This suggests that apoB may be the primary driver of atherosclerosis and that lowering the concentration of all apoB-containing lipoproteins should be the focus of therapeutic strategies.
引用
- Marston, Giugliano, Melloni, et al. Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content. JAMA Cardiol. 2022. PMID: 34773460. doi:10.1001/jamacardio.2021.5083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。